These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29044459)

  • 1. Azacitidine-induced Sweet syndrome: Two unusual clinical presentations.
    Tiwari SM; Caccetta T; Kumarasinghe SP; Harvey N
    Australas J Dermatol; 2018 Aug; 59(3):e224-e225. PubMed ID: 29044459
    [No Abstract]   [Full Text] [Related]  

  • 2. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
    Alencar C; Abramowtiz M; Parekh S; Braunshweig I; Jacobson M; Silverman L; Verma A
    Am J Hematol; 2009 Oct; 84(10):688-9. PubMed ID: 19722261
    [No Abstract]   [Full Text] [Related]  

  • 3. Recurrence of abdominal large-vessel vasculitis and development of severe Sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndrome.
    Kawano H; Suzuki T; Ishii S; Wakahashi K; Kawano Y; Sada A; Minagawa K; Ueno D; Yamasaki T; Itoh T; Yokozaki H; Katayama Y
    Eur J Haematol; 2014 Apr; 92(4):362-4. PubMed ID: 24341928
    [No Abstract]   [Full Text] [Related]  

  • 4. Histiocytoid Sweet's syndrome potentially related to decitabine in a patient with myelodysplastic syndrome.
    Park JY; Park JS; Kim YC
    Eur J Dermatol; 2012; 22(6):811-2. PubMed ID: 23178879
    [No Abstract]   [Full Text] [Related]  

  • 5. Azacytidine induced localized Sweets syndrome in Myelodysplastic syndrome.
    Dev T; Dudani P; Bhari N
    Dermatol Ther; 2021 Mar; 34(2):e14754. PubMed ID: 33406304
    [No Abstract]   [Full Text] [Related]  

  • 6. Azacitidine-associated Sweet's syndrome.
    Trickett HB; Cumpston A; Craig M
    Am J Health Syst Pharm; 2012 May; 69(10):869-71. PubMed ID: 22555082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemia cutis in myelodysplastic syndrome and chronic myelomonocytic leukemia patients treated with adjusted dose 5-azacitidine.
    Infante MS; Muñoz C; Heras C; Foncillas MA; González I; Lucea I; Echavarria E; Aramendi T; Hernández JA
    Eur J Dermatol; 2015; 25(6):622-3. PubMed ID: 26552844
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
    Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
    Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azacitidine is effective for the treatment of myelodysplastic syndrome and accompanied Sweet syndrome.
    Lin CH; Yeh SP; Lin TY
    Ann Hematol; 2015 Nov; 94(11):1925-6. PubMed ID: 26233682
    [No Abstract]   [Full Text] [Related]  

  • 10. Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.
    Peterlin P; Cluzeau T; Jullien M; Ngo Nloga AM; Calleja A; Angeli E; Chevallier P; Guillaume T; Garnier A; Le Bourgeois A; Le Gouill S; Fenaux P; Adès L; Bally C
    Br J Haematol; 2020 Aug; 190(3):461-464. PubMed ID: 32394477
    [No Abstract]   [Full Text] [Related]  

  • 11. Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.
    Prebet T; Fenaux P; Vey N;
    Haematologica; 2016 Oct; 101(10):e427-e428. PubMed ID: 27694503
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.
    Liu Y; Tabarroki A; Billings S; Visconte V; Rogers HJ; Hasrouni E; Englehaupt R; Kalaycio M; Sekeres MA; Saunthararajah Y; Tiu RV
    Leuk Lymphoma; 2014 Feb; 55(2):447-9. PubMed ID: 23647061
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
    Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
    Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythematous plaques with Fever and leukocytosis.
    Guevara-Gutiérrez E; Tlacuilo-Parra A; Uribe-Jiménez E
    Arch Dermatol; 2005 Feb; 141(2):263-8. PubMed ID: 15724028
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.
    Waespe N; Van Den Akker M; Klaassen RJ; Lieberman L; Irwin MS; Ali SS; Abdelhaleem M; Zlateska B; Liebman M; Cada M; Schechter T; Dror Y
    Haematologica; 2016 Dec; 101(12):1508-1515. PubMed ID: 27540140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
    Meers S; Selleslag D; Potier H; Glasmacher A; Mineur P; Voelter V
    Curr Med Res Opin; 2015 Jan; 31(1):35-42. PubMed ID: 25317956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there an association between 5-azacitidine and ototoxicity?
    Malik A; Misbah S; Spaccavento C; Yudelman I
    J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015
    [No Abstract]   [Full Text] [Related]  

  • 18. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.
    Voso MT; Niscola P; Piciocchi A; Fianchi L; Maurillo L; Musto P; Pagano L; Mansueto G; Criscuolo M; Aloe-Spiriti MA; Buccisano F; Venditti A; Tendas A; Piccioni AL; Zini G; Latagliata R; Filardi N; Fragasso A; Fenu S; Breccia M;
    Eur J Haematol; 2016 Apr; 96(4):344-51. PubMed ID: 26018238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
    Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
    Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.